News & Events
Introducing Disc Medicine, a New Hematology Company
Introducing Disc Medicine – we are a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell productions (erythropoiesis). Focused on the hepcidin pathway, the master regulator of iron metabolism and the most promising consensus pathway to address a range of diseases, Disc is advancing first-in-class therapies to transform how hematologic disease is treated. We are led by an experienced team of scientists and industry experts, and supported by a panel of advisors with a strong track record of discovering and developing new and innovative therapies.
Innovation in the treatment of hematologic disease has been fleeting – blood transfusions, which are not appropriate for many patients, have been the foundation of hematology for 50 years. We see the challenges faced by those with anemias, myelodysplastic syndrome, myeloproliferative disorders, thalassemia, and anemia of chronic disease, and seek to change the options that are available to these patients. At Disc Medicine, we are breathing new life into hematology drug discovery and development.
Follow us on Twitter and Linkedin for company updates and announcements.
John Quisel, JD, PhD Joins Disc Me…
Cambridge, Mass. – January 28, 2020 – Disc Medicine, a hematology company applying new insights in hepcidin biology to develop therapies that restore red…read more
Disc Medicine Completes $50 Millio…
Disc Medicine, a hematology company applying new insights in hepcidin biology to develop therapies that restore red blood cell production in hematologic dise…read more
Disc Medicine Expands Pipeline Foc…
Enters into exclusive agreement with AbbVie for series of Hemojuvelin Antagonist Monoclonal Antibodies Cambridge, Mass. – October 29, 2019 – Disc Medicin…read more
Introducing Disc Medicine, a New H…
Introducing Disc Medicine – we are a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell productions (eryt…read more